Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Early Phase 1
2(66.7%)
Phase 1
1(33.3%)
3Total
Early Phase 1(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03999229Phase 1Recruiting

S-Nitrosylation (SNO) Therapy During Autologous Blood Transfusion

Role: lead

NCT04528771Early Phase 1Withdrawn

S-Nitrosylation Therapy of COVID-19

Role: lead

NCT03926741Early Phase 1Completed

GSNOR Phenotyping/GSNO Challenge in Severe Asthma

Role: lead

All 3 trials loaded